Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01361555 · ClinicalTrials.gov registry record · Phase 2
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 789
- Enrollment target
NCT01361555 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 789 participants.
The verdict
NCT01361555, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 789 participants
- Enrollment target
Study Summary
The purpose of this study it to evaluate the long-term safety and tolerability of BMS-820836 in patients with depression.
Interventions
- DRUG BMS-820836
- DRUG Placebo matching with BMS-820836
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 789 participants |
| Start Date | 2011-08 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01361555
The ClinicalTrials.gov registry entry for NCT01361555 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 789 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-820836 is the first listed.
NCT01361555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01361555 about?
NCT01361555 is a clinical study titled "Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression". The purpose of this study it to evaluate the long-term safety and tolerability of BMS-820836 in patients with depression.
What is the current status of trial NCT01361555?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 789 participants. The study started on 2011-08. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01361555?
The interventions under investigation include: BMS-820836 (DRUG), Placebo matching with BMS-820836 (DRUG).
Who is sponsoring clinical trial NCT01361555?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.